NCT07635082

Who might be able to join this trial:

• Women who have been diagnosed with polycystic ovary syndrome (PCOS) using a standard set of medical guidelines called the Rotterdam criteria.
• Women whose PCOS has not responded to a fertility medication called letrozole — meaning they did not ovulate after taking letrozole (5 mg daily for 5 days) across three treatment cycles.
• Women between the ages of 18 and 35 years old.
• Women with a body mass index (BMI) of 30 or below (a measure of body weight relative to height).
• Women whose uterus and fallopian tubes have been confirmed to be healthy and unblocked through specific medical tests.
• Women whose male partner has had a normal sperm test.
• Women who are willing and able to give their written agreement to take part in the trial.

Who may not be able to join:

• Women who have a thyroid condition that affects how their thyroid gland works.
• Women who have higher-than-normal levels of a hormone called prolactin.
• Women who have diabetes.
• Women who have a condition called congenital adrenal hyperplasia (a hormone disorder present from birth).
• Women whose high androgen (male hormone) levels are caused by a problem with their adrenal glands.
• Women who are taking medications that help the body use insulin more effectively, such as metformin, during the study period.
• Women who have a long-term liver condition.
• Women who have a long-term kidney condition.
• Women who have any medical reason why pregnancy would not be safe for them (confirm with trial site).
• Women who are allergic to, or have a medical reason not to take, either inositol or letrozole.

Important: Always verify eligibility with the trial site directly before applying.